# US 10,149,873 B2 · Subfamily E simian adenoviruses A1321, A1325, A1295, A1309, A1316 and A1322 and uses thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,149,873 B2 - Document ID: US10149873B2 - Status: Granted - Kind: B2 - Application number: 15/172,938 - Filed: 2016-06-03 - Published: 2016-09-22 - Granted: 2018-12-11 - Earliest claimed: 2010-11-23 - Assignees: The Trustees of the University of Pennsylvania - Applicants: The Trustees of the University of Pennsylvania - Inventors: Soumitra Roy; James M. Wilson - Web page: https://patentgrep.com/patent/US10149873B2 ## CPC - A61K 35/761: Adenovirus - C07K 14/005: from viruses - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - C12N 15/86: Viral vectors - A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy - C12N 2710/10021: Viruses as such, e.g. new isolates, mutants or their genomic sequences - C12N 2710/10022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N 2710/10041: Use of virus, viral particle or viral elements as a vector - C12N 2710/10043: viral genome or elements thereof as genetic vector - C12N 2710/10321: Viruses as such, e.g. new isolates, mutants or their genomic sequences - C12N 2710/10322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N 2710/10334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - C12N 2710/10343: viral genome or elements thereof as genetic vector - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract Recombinant vectors comprise simian adenovirus A1321 (SAdV-A1321), SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-A1321, SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided. ## Claims ### Claim 1 An adenovirus having a capsid comprising a hexon protein, a penton protein, and a fiber protein, wherein said hexon protein is the hexon protein of SAdV-A1321 with the amino acids 1 to 942 of SEQ ID NO: 10, and wherein said penton protein is the penton protein of SAdV-A1321 with the amino acids 1 to 540 of SEQ ID NO: 5; said capsid encapsidating a heterologous nucleic acid comprising a gene operably linked to expression control sequences which direct transcription, translation, and/or expression thereof in a host cell. ### Claim 2 (depends on 1) The adenovirus according to claim 1, further comprising a 5′ and a 3′ adenovirus cis-element necessary for replication and encapsidation. ### Claim 3 (depends on 1) The adenovirus according to claim 1, wherein said adenovirus lacks all or a part of the E1 gene. ### Claim 4 (depends on 3) The adenovirus according to claim 3, wherein said adenovirus is replication-defective. ### Claim 5 (depends on 1) The adenovirus according to claim 1, wherein said fiber protein is the fiber protein of SAdV-A1321 with the amino acids 1 to 445 of SEQ ID NO: 19. ### Claim 6 (depends on 1) The adenovirus according to claim 1, wherein said capsid is a hybrid capsid. ### Claim 7 (depends on 6) The adenovirus according to claim 6, wherein said hybrid capsid comprises at least one capsid protein from an adenovirus selected from SAdV-A1316, SAdV-1322, and SAdV-A1325. ### Claim 8 (depends on 1) A composition comprising the adenovirus according to claim 1 in a pharmaceutically acceptable carrier. ### Claim 9 (depends on 1) A composition comprising an adenovirus according to claim 1, said adenovirus further comprising at least one simian adenovirus protein selected from the group consisting of: E1a, SEQ ID NO: 27; E1b, small T/19K, SEQ ID NO: 2; E1b, large T/55K, SEQ ID NO: 21; IX, SEQ ID NO: 3; IIIa, SEQ ID NO: 4; VII, SEQ ID NO: 6; V, SEQ ID NO: 7; pX, SEQ ID NO: 8; VI, SEQ ID NO: 9; Endoprotease, SEQ ID NO: 11; 100 kD, SEQ ID NO: 12; 22 kD, SEQ ID NO: 22; VIII, SEQ ID NO: 13; CR1-alpha SEQ ID NO: 14; gp19K, SEQ ID NO: 23; CR1-beta, SEQ ID NO: 15; CR1-gamma, SEQ ID NO: 16; CR1-delta, SEQ ID NO: 24; RID-alpha, SEQ ID NO: 17; RID-beta, SEQ ID NO: 18; E3/14.7K, SEQ ID NO: 25; and Fiber, SEQ ID NO: 19. ### Claim 10 An adenovirus having a capsid comprising a hexon protein, a penton protein, and a fiber protein, wherein said hexon protein is the hexon protein of SAdV-A1321 with the amino acids 1 to 942 of SEQ ID NO: 10, and wherein said fiber protein is the fiber protein of SAdV-A1321 with the amino acids 1 to 445 of SEQ ID NO: 19; said capsid encapsidating a heterologous nucleic acid comprising a gene operably linked to expression control sequences which direct transcription, translation, and/or expression thereof in a host cell. ### Claim 11 (depends on 10) The adenovirus according to claim 10, further comprising a 5′ and a 3′ adenovirus cis-element necessary for replication and encapsidation. ### Claim 12 (depends on 10) The adenovirus according to claim 10, wherein said adenovirus lacks all or a part of the E1 gene. ### Claim 13 (depends on 12) The adenovirus according to claim 12, wherein said adenovirus is replication defective. ### Claim 14 (depends on 10) The adenovirus according to claim 10, wherein said capsid is a hybrid capsid. ### Claim 15 (depends on 14) The adenovirus according to claim 14, wherein said hybrid capsid comprises at least one capsid protein from an adenovirus selected from SAdV-A1316, SAdV-1322, and SAdV-A1325. ### Claim 16 (depends on 10) A composition comprising the adenovirus according to claim 10 in a pharmaceutically acceptable carrier. ### Claim 17 (depends on 10) A composition comprising an adenovirus according to claim 10, said adenovirus further comprising at least one simian adenovirus protein selected from the group consisting of: E1a, SEQ ID NO: 27; E1b, small T/19K, SEQ ID NO: 2; E1b, large T/55K, SEQ ID NO: 21; IX, SEQ ID NO: 3; IIIa, SEQ ID NO: 4; Penton, SEQ ID NO: 5; VII, SEQ ID NO: 6; V, SEQ ID NO: 7; pX, SEQ ID NO: 8; VI, SEQ ID NO: 9; Endoprotease, SEQ ID NO: 11; 100 kD, SEQ ID NO: 12; 22 kD, SEQ ID NO: 22; VIII, SEQ ID NO: 13; CR1-alpha SEQ ID NO: 14; gp19K, SEQ ID NO: 23; CR1-beta, SEQ ID NO: 15; CR1-gamma, SEQ ID NO: 16; CR1-delta, SEQ ID NO: 24; RID-alpha, SEQ ID NO: 17; RID-beta, SEQ ID NO: 18; and E3/14.7K, SEQ ID NO: 25.